Carisma Therapeutics, Inc.
CARM
Rank in Stocks
#34659
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing... Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Share Price
$0.0002
Last synced: 2026-11-09
Market Cap
$8.37K
Change (1 day)
0.00%
Change (1 year)
-99.58%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Carisma Therapeutics, Inc. (CARM)
Category
Healthcare
EPS for Carisma Therapeutics, Inc. (CARM)
EPS as of September 2025 TTM: $0.20
According to Carisma Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $0.20. At the end of 2024 the company had an EPS of $-1.46, an increase over its 2023 EPS of $-2.59.
EPS history for Carisma Therapeutics, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.20 | -113.70% |
| 2024 | $-1.46 | -43.63% |
| 2023 | $-2.59 | 70.39% |
| 2022 | $-1.52 | 4,030.43% |
| 2021 | $-0.04 | -99.03% |
| 2020 | $-3.81 | -83.88% |
| 2019 | $-23.64 | 116.68% |
| 2018 | $-10.91 | -50.94% |
| 2017 | $-22.24 | -1,342.46% |
| 2016 | $1.79 | -105.08% |
| 2015 | $-35.23 | -25.30% |
| 2014 | $-47.16 | 3.65% |
| 2013 | $-45.50 | -18.31% |
| 2012 | $-55.70 | 83.28% |
| 2011 | $-30.39 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 7,730.00% |
US
|
|
| $-7.07 | -3,635.00% |
US
|
|
| $-5.29 | -2,745.00% |
AU
|
|
| $12.88 | 6,340.05% |
BE
|
|
| $21.56 | 10,680.00% |
NL
|
Questions about Carisma Therapeutics, Inc.'s earnings per share (EPS)
What is Carisma Therapeutics, Inc.'s earnings per share (EPS)?
Carisma Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $0.20, as of Sep 2025.
What was Carisma Therapeutics, Inc.'s earnings per share (EPS) in 2024?
In 2024, Carisma Therapeutics, Inc.'s earnings per share (EPS) was $-1.46, compared with $-2.59 in 2023.
How has Carisma Therapeutics, Inc.'s earnings per share (EPS) changed since 2019?
From 2019 to 2024, Carisma Therapeutics, Inc.'s earnings per share (EPS) was highest in 2021 ($-0.04) and lowest in 2019 ($-23.64).
How does Carisma Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Carisma Therapeutics, Inc.'s earnings per share (EPS) ($0.20) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.